Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccinex, Inc. - Common Stock (NQ: VCNX )

1.410 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.410
Bid (Size) 1.320 (1)
Ask (Size) 1.460 (2)
Prev. Close 1.410
Today's Range 1.410 - 1.410
52wk Range 1.390 - 13.02
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?
Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Nasdaq. Here's what you need to know. 
Via Benzinga

Performance

YTD
-86.64%
-86.64%
1 Month
-60.83%
-60.83%
3 Month
-68.60%
-68.60%
6 Month
-76.77%
-76.77%
1 Year
-85.66%
-85.66%

More News

Read More
Crude Oil Down Over 1%; US Industrial Production Declines In November
Via Benzinga
Exposures Fossil Fuels
Dow Dips Over 200 Points; US Retail Sales Top Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024
Via InvestorPlace
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With Vaccinex Stock Wednesday?
Via Benzinga
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
From Vaccinex, Inc.
Via GlobeNewswire
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.